• Contact: +91-9643310025, 9643312749
  • Generic selectors
    Exact matches only
    Search in title
    Search in content
    Search in posts
    Search in pages
    Filter by Categories
    Annual brand plans
    Autoimmune diseases
    Blog
    Conference support
    Corporate strategy and R & D consulting
    KOL support
    Medical
    MSL training
    Orphan Diseases
    Pre-& post launch activities
    Sales & marketing
    Sales force training
Pharmintel

CORONAVIRUS PIPELINE: ARE WE READY WITH DRUGS/VACCINES?

Posted by pharmintel on February 21, 2020

0
Category: Blog
The novel coronavirus outbreak in China, Wuhan has been termed as Covid-19, is spreading rapidly to other countries and millions of lives are endangered. This pandemic has catalyzed the development of novel coronavirus vaccines in the industry and several companies are coming up with treatment and therapy for this deadly virus. Recently Favilavir, an anti-viral drug, as a treatment for Coronavirus has been approved by the National Medical Products Administration of China. The drug reportedly has

Sales Target

Posted by pharmintel on February 17, 2020

0
Category: Blog
It’s an important factor for sales personals to accomplish sales target. Sales target plays an important role in companies’ annual turnover, market share, profitability, number of new account and renewal of existing contracts, etc. Sales target is the driving factor of company’s growth but under performing sales employees make it vulnerable. For most of the sales employees it becomes a tedious job to meet targets which are exceeding limits. To understand how to beat sales
Tagrisso does not meet the criteria set up by NICE’s to be considered as a life-extending treatment. Data suggest that patients who take Tagrisso live longer than their peers who receive Roche’s Tarceva (erlotinib) or AstraZeneca’s own Iressa (gefitinib). However, AstraZeneca was not able to share any information from a randomized clinical trial comparing Tagrisso to Boehringer Ingelheim’s Gilotrif (afatinib) which is the first choice, EGFR tyrosine kinase inhibitor and this may prove to be

Wait over!! Alzheimer’s treatment is on the way…

Posted by pharmintel on January 12, 2020

0
Category: Blog
In a phase II, multi-centre, randomized double blind placebo-controlled study, GemVax’s experimental drug ‘GV1001’ met its primary endpoint in moderate to severe Alzheimer’s patients. Primary endpoint in this study was SIB (Severe Impairment Battery) at week 24. SIB is a reliable cognitive measure for evaluating treatment response in advanced Alzheimer’s disease (AD). The SIB score of the control group treated with donepezil only decreased by 7.23, while that of the experimental group treated with GV1001
Multiple myeloma is the second most common blood cancer, with approximately 32,000 and 138,500 new diagnoses in the U.S. and world respectively. It is characterized by the proliferation of cancerous plasma cells (multiple myeloma cells) that crowd out healthy blood cells in the bone marrow, infiltrate other tissues and cause potentially life-threatening organ injury. Recent advances, such as CD38 antibody treatment, have increased life expectancy of patients from 3-4 years to 7-8 years. Despite this,
Contact
+91 9643310025, 9643312749
© 2020 Pharmintel